AN2 Therapeutics, Inc. Common Stock (ANTX) Stock
NASDAQ · ANTX
4.88
Fundamentals
Market cap
$184.15M
Price / Earnings ratio
-5.1x
Price / Sales ratio
N/A
Price / Book ratio
2.4x
Return on assets
-47.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
NeutralANTXSeptember 16, 2026
Business WireNeutral
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
ANTX

Business Wire
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
NeutralANTXAugust 31, 2026
Business WireNeutral
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
ANTX

Business Wire
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
NeutralANTXAugust 24, 2026
Business WireNeutral
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
ANTX

Business Wire
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
NeutralANTXAugust 11, 2026
Business WireNeutral
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
ANTX
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy1
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
74M49M25M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-35.2M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Business Wire
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
NeutralANTXSeptember 16, 2026
Business WireNeutral
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
ANTX

Business Wire
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
NeutralANTXAugust 31, 2026
Business WireNeutral
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
ANTX

Business Wire
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
NeutralANTXAugust 24, 2026
Business WireNeutral
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
ANTX

Business Wire
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
NeutralANTXAugust 11, 2026
Business WireNeutral
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
ANTX

Business Wire
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
NeutralANTXJune 4, 2026
Business WireNeutral
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
ANTX

Business Wire
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
NeutralANTXMay 21, 2026
Business WireNeutral
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
ANTX

Business Wire
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
NeutralANTXMay 11, 2026
Business WireNeutral
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
ANTX

Business Wire
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
NeutralANTXMay 7, 2026
Business WireNeutral
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
ANTX

Business Wire
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
NeutralANTXMarch 31, 2026
Business WireNeutral
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
ANTX

Business Wire
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
NeutralANTXMarch 17, 2026
Business WireNeutral
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
ANTX
About AN2 Therapeutics, Inc. Common Stock
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
SectorHealthcare
IndustryBiotechnology
Employees21
CEOMr. Eric E. Easom
IPO DateMar 23, 2022
HeadquartersMenlo Park, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Eric E. Easom | Co-Founder, CEO, President & Chairman of the Board | 1968 |
| Mr. Joseph S. Zakrzewski | Co-Founder & Independent Director | 1962 |
| Ms. Lucy O. Day CPA | CFO, & Principal Financial Officer | 1960 |
| Mr. Joshua M. Eizen J.D. | Chief Legal Officer, COO & Corporate Secretary | 1979 |
| Dr. George Harrison Talbot FACP, M.D. | Co-Founder & Senior Clinical Advisor | 1948 |
| Dr. Michael R. K. Alley Ph.D. | Co-Founder, Senior VP of Research Fellow & Head of Biology | — |
| Ms. Sarah Williams | Vice President of Controller & Principal Accounting Officer | 1988 |
| Dr. Sanjay Chanda Ph.D. | Chief Development Officer | 1966 |
| Mr. Vince Hernandez | Senior VP of Research & Head of Chemistry | — |
| Dr. Cameron Trenor III | Chief Medical Officer | — |
Fundamentals
Valuation
Market cap$184.15M
Price-to-sales ratioN/A
Price-to-book value2.43
Price-earnings ratio-5.10
Return on Equity-52.00%
Return on SalesN/A
Return on Assets-47.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.06
Income Statement
Average volume237,214
EBITDA$-34.55M
1 year high (52w)$7.19
1 year low (52w)$1.00
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
1 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$9.00
Est return
84.43%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +155.2 | +31.9 | -7.5 | +15.0 | +13.8 | -0.5 | -10.9 |



